Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - hydrochlorothiazide,irbesartan -

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - aspirin,dipyridamole -

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - meloxicam -

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - meloxicam -

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - meloxicam -

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - meloxicam -

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - nizatidine, quantity: 300 mg - capsule, hard - excipient ingredients: dimeticone 350; purified talc; pregelatinised maize starch; povidone; maize starch; croscarmellose sodium; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; ethanol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; iron oxide yellow; iron oxide red; gelatin - tazac is indicated for up to 8 weeks for the treatment of active duodenal ulcer. in most patients, the ulcer will heal within 4 weeks. tazac is also indicated for maintenance therapy for duodenal ulcer patients, at a reduced dosage of 150 mg h.s. after healing of active duodenal ulcer. continuous therapy with nizatidine for longer than 1 year has not been studied. tazac is indicated for up to 8 weeks for the treatment of benign gastric ulcer. tazac is indicated for up to 12 weeks for the treatment of oesophagitis, including erosive and ulcerative oesophagitis and associated heartburn due to reflux.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - furosemide, quantity: 40 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; magnesium stearate; maize starch - indications as at 01 jan 1991 : oedema : in adults, infants and children frusemide is indicated for the treatment of oedema associated with congestive heart failure, cirrhosis of the liver, renal disease including nephrotic syndrome and other oedematous states amenable to diuretic therapy. hypertension : may also be used alone in the control of mild to moderate hypertension and in combination with other antihypertensive agents in the treatment of more severe cases. studies have shown that frusemide is either less effective than or equally effective as thiazide diuretics in uncomplicated hypertension. however, in patients with severe renal function impairment, a diuretic and antihypertensive response to frusemide may be achieved while thiazides have no effect.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - acetazolamide, quantity: 250 mg - tablet, uncoated - excipient ingredients: maize starch; calcium hydrogen phosphate dihydrate; magnesium stearate; povidone; sodium starch glycollate - for adjunctive treatment of oedema due to congestive heart failure; drug induced oedema; centrencephalic epilepsies (petit mal, unlocalised seizures); chronic simple (open angle) glaucoma, secondary glaucoma and preoperatively in acute angle closure glaucoma where delay of surgery is desired in order to lower intraocular pressure.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - rosuvastatin calcium -